Skip to Content

Aurora Cannabis Inc ACB Stock Quote

| Rating as of

Morningstar‘s Stock Analysis ACB

Currency in CAD

Economic Moat


Capital Allocation


Aurora More Than Halves EBITDA Losses in FY 2022 but Continues to Dilute Existing Shareholders

Analyst Note

| Kristoffer Inton |

Aurora's cost-cutting efforts bore fruit in FY 2022 as adjusted EBITDA losses fell by more than half to CAD 51 million from CAD 114 million in FY 2021. This progress is particularly impressive given that net revenue actually declined by 10% year over year to CAD 221 million. Management has targeted positive adjusted EBITDA by its second fiscal quarter ending Dec. 31, 2022, but we'd be surprised by such rapid improvement. Fourth-quarter adjusted EBITDA losses alone were nearly CAD 13 million, so some combination of better revenue growth, higher gross margin, or larger cuts to overhead expenses than we expect would need to happen. We think the company will reach positive adjusted EBITDA roughly a year later, sometime in fiscal year 2024.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ACB

Company Profile ACB

Business Description

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.

500-10355 Jasper Avenue
Edmonton, AB, T5J 1Y6, Canada
T +1 855 279-4652
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2022
Fiscal Year End Jun 30, 2022
Employees 1,338